Partnership for Innovations to Fight Infectious Diseases and Leave No One Behind

Osamu Kunii, MD, MPH, PhD

CEO & Executive Director

Global Health Innovative Technology

(GHIT) Fund

Innovation in 21st century partnership

1. Gavi the Vaccine Alliance

The Global Fund to fight AIDS, Tuberculosis and Malaria


The Health Campus

介

In Geneva, Switzerland



Rapid drop of life span in African countries





POWER OF PARTNERSHIP

- Not just information sharing
- Sharing responsibility for actions with common goal
- At all level : global, regional and country
- With all regions : Asia, Africa, Latin America, E. Europe
- With all sector : governments, UN/international organizations, academia, private foundations, industries, NGOs, civil society


MECHANISMS FOR PARTNERSHIP

- Decision making : Board, Committees
- Fund raising
- Regional networking
- Country level:
- Ownership : support national plan and health system
- Country Coordination Mechanism (CCM)
- Strengthen civil society

Scaled up essential services


- HIV % of people living with HIV on antiretroviral therapy
- Tuberculosis % of TB treatment coverage

O Malaria - % of population with access to a long-lasting insecticide-treated net




100%


Rapid drop of deaths due to AIDS in Botswana



Source: UNAIDS Report on the Global AIDS Epidemic – 2012.


Impact (lives saved)





Left: Photograph by David Walton. Copyright 2002 © Partners in Health. All rights reserved. Right: Photograph by David Walton. Copyright 2003 © Partners in Health. All rights reserved.

Global Health Innovative Technology Fund (GHIT)



GHIT Fund | Management Team | 13

Poverty-related Diseases affect Neglected People


- Tuberculosis
- Malaria
- **Neglected Tropical Diseases** (NTDs)

2 billion Cases **Deaths 2 million**

Neglected Tropical Diseases (NTDs)









Chagas disease Dengue fever (American trypanosomiasis)

Echinococcosis

Leishmaniasis



Lymphatic filariasis

(elephantiasis)

Buruli ulcer







Schistosomiasis (bilharziasis)

Soil-transmitted helminthiases (intestinal parasitic worms)



Dracunculiasis (guinea-worm diseases)

scabies



Mycetoma



Human African trypanosomiasis (sleeping sickness)

Onchoserciasis

(river blindness)







Leprosy



Rabies


Cysticercosis


Endemic treponematoses (including yaws)



infections














Low success rate from drug discovery to approval




Global Partnership





COVID-19 also brought opportunities



Development of COVID-19 Vaccines



821 Vaccine Trials






As of Oct 2023


COVID Vaccine Tracker https://covid19.trackvaccines.org/vaccines/

COVID-19 Deaths reported worldwide



Source: IHME

Emerging and Reemerging diseases




UK Cornwall G7 Summit in 2021



to respond to future pandemic threats

ailaible. Safe, Effective, Affordable





An initial regimen of **therapeutics**




Vaccines ready to be produced at scale

G7


100 DAYS

MISSION

Global key stakeholders to achieve 100DM



Access & Delivery (A&D) matters



What are key to achieve 100DM?

- Sharing samples, data and information
- Technical transfer of R&D and A&D
- Global networking and alignment of clinical trials and approval process
- Local/Regional manufacturing, procurement